Geode Capital Management
STRO icon

Geode Capital Management’s Sutro Biopharma STRO Stock Holding History

Geode Capital Management’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.27M Buy
171,386
+87,407
+104% +$1.58M ﹤0.01% 2820
2025
Q4 		$972K Buy
83,979
+1,884
+2% +$17.9K ﹤0.01% 3385
2025
Q3 		$713K Buy
82,095
+403
+0.5% +$3.43K ﹤0.01% 3498
2025
Q2 		$583K Sell
81,692
-107,235
-57% -$877K ﹤0.01% 3503
2025
Q1 		$1.23M Buy
188,927
+3,525
+2% +$55.5K ﹤0.01% 3233
2024
Q4 		$3.41M Sell
185,402
-294
-0.2% -$8.97K ﹤0.01% 2928
2024
Q3 		$6.43M Buy
185,696
+13,202
+8% +$517K ﹤0.01% 2630
2024
Q2 		$5.05M Buy
172,494
+43,862
+34% +$1.73M ﹤0.01% 2712
2024
Q1 		$7.27M Buy
128,632
+2,708
+2% +$120K ﹤0.01% 2510
2023
Q4 		$5.4M Buy
125,924
+6,209
+5% +$197K ﹤0.01% 2662
2023
Q3 		$4.15M Buy
119,715
+3,562
+3% +$155K ﹤0.01% 2734
2023
Q2 		$5.4M Buy
116,153
+10,522
+10% +$524K ﹤0.01% 2642
2023
Q1 		$4.88M Buy
105,631
+3,523
+3% +$224K ﹤0.01% 2634
2022
Q4 		$8.25M Buy
102,108
+17,033
+20% +$1.18M ﹤0.01% 2386
2022
Q3 		$4.72M Buy
85,075
+3,596
+4% +$213K ﹤0.01% 2709
2022
Q2 		$4.25M Buy
81,479
+2,599
+3% +$145K ﹤0.01% 2793
2022
Q1 		$6.48M Buy
78,880
+4,512
+6% +$429K ﹤0.01% 2638
2021
Q4 		$11.1M Buy
74,368
+5,170
+7% +$926K ﹤0.01% 2375
2021
Q3 		$13.1M Buy
69,198
+1,427
+2% +$271K ﹤0.01% 2267
2021
Q2 		$12.6M Buy
67,771
+11,106
+20% +$2.17M ﹤0.01% 2296
2021
Q1 		$12.9M Buy
56,665
+14,813
+35% +$3.51M ﹤0.01% 2175
2020
Q4 		$9.09M Buy
41,852
+9,804
+31% +$1.62M ﹤0.01% 2240
2020
Q3 		$3.22M Buy
32,048
+5,816
+22% +$549K ﹤0.01% 2632
2020
Q2 		$2.04M Buy
26,232
+14,287
+120% +$1.37M ﹤0.01% 2825
2020
Q1 		$1.22M Buy
11,945
+2,323
+24% +$244K ﹤0.01% 2929
2019
Q4 		$1.06M Buy
9,622
+384
+4% +$39.6K ﹤0.01% 3260
2019
Q3 		$839K Buy
9,238
+59
+0.6% +$5.96K ﹤0.01% 3287
2019
Q2 		$1.04M Buy
9,179
+3,817
+71% +$421K ﹤0.01% 3231
2019
Q1 		$610K Buy
5,362
+302
+6% +$31.4K ﹤0.01% 3354
2018
Q4 		$456K Buy
+5,060
New +$611K ﹤0.01% 3406

Other funds holding STRO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Geode Capital Management's STRO Position: Q1 2026 in Review

Geode Capital Management increased its Sutro Biopharma (STRO) stake by 104% in Q1 2026, buying an estimated $1.58M and bringing the position to 171,386 shares worth $4.27M. The position accounts for ﹤0.01% of the portfolio, ranked #2820.

Geode Capital Management first reported a position in STRO in Q4 2018 and has held it in 30 quarters since. The position peaked at $13.1M in Q3 2021. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

  • Geode Capital Management held 171,386 shares of Sutro Biopharma worth $4.27M as of Q1 2026.
  • Geode Capital Management bought 87,407 Sutro Biopharma shares in Q1 2026, an estimated $1.58M.
  • Sutro Biopharma made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2820 holding.
  • Geode Capital Management first reported a position in Sutro Biopharma in Q4 2018 and has held it in 30 quarters since.
  • Geode Capital Management's Sutro Biopharma position peaked at $13.1M in Q3 2021.
  • 78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.